Ocugen, based in Malvern, PA, develops novel biological and repurposed drug therapies for sight-threatening conditions. The company is advancing two novel biologics and a marketed product via the FDA’s 505(b)(2) pathway. Lead programs include OCU100, a recombinant lens epithelium-derived growth factor with orphan-drug status for retinitis pigmentosa; OCU200, an anti-angiogenic tumstatin fusion protein for wet AMD; and OCU300, a 505(b)(2) candidate for ocular graft-versus-host disease. Ocugen is led by Chairman, CEO and co-founder Dr. Shankar Musunuri. The company intends to use recent funding to advance potential sight-saving ophthalmology products into clinical trials. Financially, it closed a $7.5M Series B to support these programmatic efforts. Ocugen is a biopharmaceutical company based in Aurora, Colorado and Malvern, Pennsylvania focused on developing treatments for sight‑threatening diseases of the eye. Its lead program, OCU300, is a repurposed drug with an established ocular safety track record being developed for ocular graft‑versus‑host disease (oGVHD) under the FDA’s 505(b)(2) regulatory pathway. The company intends to use the Series A proceeds to advance OCU300 toward an IND submission within a year. Ocugen has a broad pipeline that includes both clinical‑stage and preclinical programs aimed at activating novel biologic pathways to treat inflammatory, degenerative, and neovascular eye diseases. Management is led by Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co‑Founder. The company closed a $6.0M Series A financing; backers included $1.0M raised through EB5 Life Sciences and Dr. Bernhard Hampl.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2017